GaoG.P., AlviraM.R., WangL., CalcedoR., JohnstonJ., WilsonJ.M.2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A., 99:11854–11859.
7.
GrimmD., KayM.A.2007. Therapeutic application of RNAi: Is mRNA targeting finally ready for prime time?J. Clin. Invest., 117:3633–3641.
8.
Hacein-Bey-AbinaS., GarrigueA., WangG.P., SoulierJ., LimA., MorillonE., ClappierE., CaccavelliL., DelabesseE., BeldjordK., AsnafiV., MacIntyreE., Dal CortivoL., RadfordI., BrousseN., SigauxF., MoshousD., HauerJ., BorkhardtA., BelohradskyB.H., WintergerstU., VelezM.C., LeivaL., SorensenR., WulffraatN., BlancheS., BushmanF.D., FischerA., Cavazzana-CalvoM.2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.
9.
LombardoA., GenoveseP., BeausejourC.M., ColleoniS., LeeY.L., KimK.A., AndoD., UrnovF.D., GalliC., GregoryP.D., HolmesM.C., NaldiniL.2007. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol., 25:1298–12306.
10.
MaguireA.M., SimonelliF., PierceE.A., PughE.N. Jr., MingozziF., BennicelliJ., BanfiS., MarshallK.A., TestaF., SuraceE.M., RossiS., LyubarskyA., ArrudaV.R., KonkleB., StoneE., SunJ., JacobsJ., Dell'OssoL., HertleR., MaJ.X., RedmondT.M., ZhuX., HauckB., ZelenaiaO., ShindlerK.S., MaguireM.G., WrightJ.F., VolpeN.J., McDonnellJ.W., AuricchioA., HighK.A., BennettJ.2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358:2240–2248.
11.
MannoC.S., PierceG.F., ArrudaV.R., GladerB., RagniM., RaskoJ.J., OzeloM.C., HootsK., BlattP., KonkleB., DakeM., KayeR., RazaviM., ZajkoA., ZehnderJ., RustagiP.K., NakaiH., ChewA., LeonardD., WrightJ.F., LessardR.R., SommerJ.M., TiggesM., SabatinoD., LukA., JiangH., MingozziF., CoutoL., ErtlH.C., HighK.A., KayM.A.2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.
12.
MátésL., ChuahM.K., BelayE., JerchowB., ManojN., Acosta-SanchezA., GrzelaD.P., SchmittA., BeckerK., MatraiJ., MaL., Samara-KukoE., GysemansC., PryputniewiczD., MiskeyC., FletcherB., VandendriesscheT., IvicsZ., IzsvákZ.2009. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet., 41:753–761.
13.
MingozziF., LiuY.L., DobrzynskiE., KaufholdA., LiuJ.H., WangY., ArrudaV.R., HighK.A., HerzogR.W.2003. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest., 111:1347–1356.
14.
ModlichU., BaumC.2009. Preventing and exploiting the oncogenic potential of integrating gene vectors. J. Clin. Invest., 119:755–758.
15.
MontiniE., CesanaD., SchmidtM., SanvitoF., BartholomaeC.C., RanzaniM., BenedicentiF., SergiL.S., AmbrosiA., PonzoniM., DoglioniC., Di SerioC., von KalleC., NaldiniL.2009. The genotoxic potential of retrovial vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therpy. J. Clin. Invest., 119:964–975.
16.
TakahashiK., YamanakaS.2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126:663–676.
